Inactief instrument

Andere talen Essex Bio-Technology Limited Deutsche Boerse AG

Aandelen

EB51

KYG312371035

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023	28/05
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	19/03
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	18/03
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	18/03
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong	03/01
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index	18-09-23
Essex Bio-Technology's Profit Jumps 22% in H1	17-08-23
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	16-08-23
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023	16-08-23
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	16-08-23
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial	27-07-23
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	26-07-23
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration	26-07-23
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility	17-07-23
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	13-06-23
Essex Bio-Technology Limited Announces Director Changes	09-06-23
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022	09-06-23
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.	09-06-23
Essex and Osteopore Entered into Exclusive Distribution Agreement	14-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Essex Bio-Technology Limited Deutsche Boerse AG

Aandelen

EB51

KYG312371035

Andere talen

Filters